Results 171 to 180 of about 7,325 (251)

Electrochemical Formation and Characterization of Functional Ag-Re Coatings. [PDF]

open access: yesMaterials (Basel)
Bersirova O   +3 more
europepmc   +1 more source

Dual Action of Dipyridamole in Experimental Rheumatoid Arthritis: Suppression of Joint Inflammation and Upregulation of Muscle Anabolism via Adenosine and AMPK pathways

open access: yesArthritis &Rheumatology, Accepted Article.
Introduction Rheumatoid sarcopenia, characterized by the progressive loss of skeletal muscle mass and function, is a frequent comorbidity in rheumatoid arthritis (RA), linked to prolonged, severe systemic inflammation. Purinergic signaling (adenosine, AMP, and ATP) plays a crucial role in inflammation, myogenesis, and muscle hypertrophy.
Miguel Marco‐Bonilla   +13 more
wiley   +1 more source

Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon   +8 more
wiley   +1 more source

Dysregulation of U12‐Type Splicing in Lupus Neutrophils

open access: yesArthritis &Rheumatology, Accepted Article.
Abstract. Objective Neutrophil dysfunction is a hallmark of systemic lupus erythematosus (SLE), but its molecular basis remains unclear. This study explores transcriptional and post‐transcriptional changes in low‐density granulocytes (LDGs), a proinflammatory neutrophil subset expanded in SLE, focusing on NADPH oxidase (Nox) function and minor intron ...
Luz P. Blanco   +11 more
wiley   +1 more source

Machine Learning-Guided Design of Rhenium Tricarbonyl Complexes for Next-Generation Antibiotics. [PDF]

open access: yesACS Bio Med Chem Au
Nedyalkova M   +11 more
europepmc   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results from the Phase 2 TULIP‐LN Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon (IFN) signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, NCT02547922). We studied
Andrea Fava   +8 more
wiley   +1 more source

Efficacy, Safety, and Patient Reported Outcomes of Rhenium-Skin Cancer Therapy for Non-Melanoma Skin Cancer: 1-Year Results from the EPIC-Skin Study. [PDF]

open access: yesAdv Radiat Oncol
Cardaci G   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy